Company:  AVADEL PHARMACEUTICALS PL ... (AVDL)
Form Type:  4
Filing Date:  7/11/2018 
CIK:  0001012477 
Address:  BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
BALLYCOOLIN
 
City, State, Zip:  DUBLIN,  15 
Telephone:  636-449-1830 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.34  
Change: 
0.02 (1.52%)  
Trade Time: 
03:59 PM EST  
Market Cap: 
$50.06M
Trade AVDL now with 

© 2019  
Description of Business
(Dollar amounts in thousands, except per-share amounts and as otherwise noted) General Overview Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel," the "Company," "we," "our," or "us") is a branded specialty pharmaceutical company. Our primarily focus is on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our "unapproved marketed drug" (UMD) program. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com..
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES